{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T16:04:43Z","timestamp":1789488283676,"version":"build-2803163510"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,9,15]]},"DOI":"10.7759\/cureus.116301","type":"journal-article","created":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T15:24:20Z","timestamp":1789485860000},"source":"Crossref","is-referenced-by-count":0,"title":["Acute Urinary Retention Leading to Post-renal Acute Kidney Injury Post-radiotherapy: A Case Report"],"prefix":"10.7759","author":[{"given":"Brayden","family":"Bitterman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nitin","family":"Vaishampayan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimberly B","family":"Hart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramesh","family":"Boggula","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven R","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/641689","article-title":"Management of high-risk localized prostate cancer","volume":"2012","author":"Marciscano AE","year":"2012","unstructured":"Marciscano AE, Hardee ME, Sanfilippo N. Management of high-risk localized prostate cancer. Adv Urol. 2012, 2012:641689. 10.1155\/2012\/641689","journal-title":"Adv Urol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.21037\/tcr-20-2589","article-title":"Urological complications after radiation therapy-nothing ventured, nothing gained: a narrative review","volume":"10","author":"Chorbi\u0144ska J","year":"2021","unstructured":"Chorbi\u0144ska J, Krajewski W, Zdrojowy R. Urological complications after radiation therapy-nothing ventured, nothing gained: a narrative review. Transl Cancer Res. 2021, 10:1096-118. 10.21037\/tcr-20-2589","journal-title":"Transl Cancer Res"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(25)00205-0","article-title":"Intensity-modulated moderately hypofractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-C): early toxicity results from a randomised, open-label, phase 3, non-inferiority trial","volume":"26","author":"Tree AC","year":"2025","unstructured":"Tree AC, Hinder V, Chan A, et al.. Intensity-modulated moderately hypofractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-C): early toxicity results from a randomised, open-label, phase 3, non-inferiority trial. Lancet Oncol. 2025, 26:936-47. 10.1016\/S1470-2045(25)00205-0","journal-title":"Lancet Oncol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.5603\/RPOR.a2023.0043","article-title":"Acute toxicity and quality of life in prostate cancer patients treated with definitive hypofractionated pelvic radiation therapy: a single-center report","volume":"28","author":"Mandel IK","year":"2023","unstructured":"Mandel IK, D\u00edaz FK, Garc\u00eda LV. Acute toxicity and quality of life in prostate cancer patients treated with definitive hypofractionated pelvic radiation therapy: a single-center report. Rep Pract Oncol Radiother. 2023, 28:316-21. 10.5603\/RPOR.a2023.0043","journal-title":"Rep Pract Oncol Radiother"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30102-4","article-title":"Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial","volume":"17","author":"Dearnaley D","year":"2016","unstructured":"Dearnaley D, Syndikus I, Mossop H, et al.. Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial. Lancet Oncol. 2016, 17:1047-60. 10.1016\/S1470-2045(16)30102-4","journal-title":"Lancet Oncol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30569-8","article-title":"Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): acute toxicity findings from an international, randomised, open-label, phase 3, non-inferiority trial","volume":"20","author":"Brand DH","year":"2019","unstructured":"Brand DH, Tree AC, Ostler P, et al.. Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): acute toxicity findings from an international, randomised, open-label, phase 3, non-inferiority trial. Lancet Oncol. 2019, 20:1531-43. 10.1016\/S1470-2045(19)30569-8","journal-title":"Lancet Oncol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-03033-0","article-title":"Impact of acute kidney injury on long-term adverse outcomes in obstructive uropathy","volume":"11","author":"Yang J","year":"2021","unstructured":"Yang J, Sun BG, Min HJ, et al.. Impact of acute kidney injury on long-term adverse outcomes in obstructive uropathy. Sci Rep. 2021, 11:23639. 10.1038\/s41598-021-03033-0","journal-title":"Sci Rep"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.21037\/amj-20-170","article-title":"Evaluation and management of urinary retention after pelvic radiation therapy","volume":"7","author":"Burns ZR","year":"2022","unstructured":"Burns ZR, Vishwanath VM, Ceballos B, Selph JP. Evaluation and management of urinary retention after pelvic radiation therapy. AME Med J. 2022, 7:2. 10.21037\/amj-20-170","journal-title":"AME Med J"},{"key":"ref9","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijrobp.2025.06.1006","article-title":"Primary results from NRG-GU005: a phase III trial of SBRT vs. hypofractionated IMRT for localized intermediate risk prostate cancer","volume":"123","author":"Ellis R","year":"2025","unstructured":"Ellis R, Pugh S, Yu J, et al.. Primary results from NRG-GU005: a phase III trial of SBRT vs. hypofractionated IMRT for localized intermediate risk prostate cancer. Int J Radiat Oncol Biol Phys. 2025,  123:S31.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2009.02.090","article-title":"Radiation dose-volume effects of the urinary bladder","volume":"76","author":"Viswanathan AN","year":"2010","unstructured":"Viswanathan AN, Yorke ED, Marks LB, Eifel PJ, Shipley WU. Radiation dose-volume effects of the urinary bladder. Int J Radiat Oncol Biol Phys. 2010, 76:S116-22. 10.1016\/j.ijrobp.2009.02.090","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2021.12.027","article-title":"Urethral and bladder dose-effect relations for late genitourinary toxicity following external beam radiotherapy for prostate cancer in the FLAME trial","volume":"167","author":"Groen VH","year":"2022","unstructured":"Groen VH, van Schie M, Zuithoff NP, et al.. Urethral and bladder dose-effect relations for late genitourinary toxicity following external beam radiotherapy for prostate cancer in the FLAME trial. Radiother Oncol. 2022, 167:127-32. 10.1016\/j.radonc.2021.12.027","journal-title":"Radiother Oncol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.02873","article-title":"Focal boost to the intraprostatic tumor in external beam radiotherapy for patients with localized prostate cancer: results from the flame randomized phase III trial","volume":"39","author":"Kerkmeijer LG","year":"2021","unstructured":"Kerkmeijer LG, Groen VH, Pos FJ, et al.. Focal boost to the intraprostatic tumor in external beam radiotherapy for patients with localized prostate cancer: results from the flame randomized phase III trial. J Clin Oncol. 2021, 39:787-96. 10.1200\/JCO.20.02873","journal-title":"J Clin Oncol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(22)00544-7","article-title":"Mechanisms, mitigation, and management of urinary toxicity from prostate radiotherapy","volume":"23","author":"Martin JM","year":"2022","unstructured":"Martin JM, Richardson M, Siva S, Cardoso M, Handmer M, Sidhom M. Mechanisms, mitigation, and management of urinary toxicity from prostate radiotherapy.  Lancet Oncol. 2022, 23:e534-43. 10.1016\/S1470-2045(22)00544-7","journal-title":"Lancet Oncol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD011462.pub2","article-title":"Hypofractionation for clinically localized prostate cancer","volume":"9","author":"Hickey BE","year":"2019","unstructured":"Hickey BE, James ML, Daly T, Soh FY, Jeffery M. Hypofractionation for clinically localized prostate cancer. Cochrane Database Syst Rev. 2019, 9:CD011462. 10.1002\/14651858.CD011462.pub2","journal-title":"Cochrane Database Syst Rev"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(25)00656-4","article-title":"Ultra-hypofractionated versus conventionally fractionated radiotherapy for localised prostate cancer (HYPO-RT-PC): 10-year outcomes of an open-label, randomised, phase 3, non-inferiority trial","volume":"27","author":"Nilsson P","year":"2026","unstructured":"Nilsson P, Gunnlaugsson A, Beckman L, et al.. Ultra-hypofractionated versus conventionally fractionated radiotherapy for localised prostate cancer (HYPO-RT-PC): 10-year outcomes of an open-label, randomised, phase 3, non-inferiority trial. Lancet Oncol. 2026, 27:293-301. 10.1016\/S1470-2045(25)00656-4","journal-title":"Lancet Oncol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2018.05.040","article-title":"Multicenter trial of stereotactic body radiation therapy for low- and intermediate-risk prostate cancer: survival and toxicity endpoints","volume":"102","author":"Meier RM","year":"2018","unstructured":"Meier RM, Bloch DA, Cotrutz C, et al.. Multicenter trial of stereotactic body radiation therapy for low- and intermediate-risk prostate cancer: survival and toxicity endpoints. Int J Radiat Oncol Biol Phys. 2018, 102:296-303. 10.1016\/j.ijrobp.2018.05.040","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.adro.2018.09.007","article-title":"Prostate stereotactic body radiation therapy with a focal simultaneous integrated boost: acute toxicity and dosimetry results from a prospective trial","volume":"4","author":"McDonald AM","year":"2019","unstructured":"McDonald AM, Dobelbower MC, Yang ES, et al.. Prostate stereotactic body radiation therapy with a focal simultaneous integrated boost: acute toxicity and dosimetry results from a prospective trial. Adv Radiat Oncol. 2019, 4:90-5. 10.1016\/j.adro.2018.09.007","journal-title":"Adv Radiat Oncol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2007.02.029","article-title":"The impact of dose escalation on secondary cancer risk after radiotherapy of prostate cancer","volume":"68","author":"Schneider U","year":"2007","unstructured":"Schneider U, Lomax A, Besserer J, Pemler P, Lombriser N, Kaser-Hotz B. The impact of dose escalation on secondary cancer risk after radiotherapy of prostate cancer. Int J Radiat Oncol Biol Phys. 2007, 68:892-7. 10.1016\/j.ijrobp.2007.02.029","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/S0733-8627(05)70205-4","article-title":"Acute urinary retention and urinary incontinence","volume":"19","author":"Curtis LA","year":"2001","unstructured":"Curtis LA, Dolan TS, Cespedes RD. Acute urinary retention and urinary incontinence. Emerg Med Clin North Am. 2001, 19:591-619. 10.1016\/S0733-8627(05)70205-4","journal-title":"Emerg Med Clin North Am"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.5114\/jcb.2016.63377","article-title":"Predictors of prostate volume reduction following neoadjuvant cytoreductive androgen suppression","volume":"8","author":"Jethwa KR","year":"2016","unstructured":"Jethwa KR, Furutani KM, Mynderse LA, et al.. Predictors of prostate volume reduction following neoadjuvant cytoreductive androgen suppression. J Contemp Brachytherapy. 2016, 8:371-8. 10.5114\/jcb.2016.63377","journal-title":"J Contemp Brachytherapy"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.70045","article-title":"Detectable prostate-specific antigen after radiotherapy for clinically localized prostate cancer","volume":"131","author":"Falagario UG","year":"2025","unstructured":"Falagario UG, Pellegrino F, Abbadi A, et al.. Detectable prostate-specific antigen after radiotherapy for clinically localized prostate cancer. Cancer. 2025, 131:e70045. 10.1002\/cncr.70045","journal-title":"Cancer"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19840501)53:9<2002::aid-cncr2820530933>3.0.co;2-w","article-title":"The Karnofsky Performance Status Scale. An examination of its reliability and validity in a research setting","volume":"53","author":"Mor V","year":"1984","unstructured":"Mor V, Laliberte L, Morris JN, Wiemann M. The Karnofsky Performance Status Scale. An examination of its reliability and validity in a research setting. Cancer. 1984, 53:2002-7. 10.1002\/1097-0142(19840501)53:9&lt;2002::aid-cncr2820530933&gt;3.0.co;2-w","journal-title":"Cancer"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/473338-acute-urinary-retention-leading-to-post-renal-acute-kidney-injury-post-radiotherapy-a-case-report","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T15:24:21Z","timestamp":1789485861000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/473338-acute-urinary-retention-leading-to-post-renal-acute-kidney-injury-post-radiotherapy-a-case-report"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,15]]},"references-count":22,"URL":"https:\/\/doi.org\/10.7759\/cureus.116301","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9,15]]}}}